Johnson, Stephanie B.
Butow, Phyllis N.
Bell, Melanie L.
Detering, Karen
Clayton, Josephine M.
Silvester, William
Kiely, Belinda E.
Clarke, Stephen
Vaccaro, Lisa
Stockler, Martin R.
Beale, Phillip
Fitzgerald, Natalie
Tattersall, Martin H. N.
Funding for this research was provided by:
Department of Health | National Health and Medical Research Council (APP10505968, APP10505968, APP10505968)
Article History
Received: 17 April 2018
Revised: 17 September 2018
Accepted: 21 September 2018
First Online: 29 October 2018
Ethics approval
: Ethics approval for the study was obtained from the: Sydney Local Health District (RPA Zone) Human Research Ethical Committee, Australia (Protocol number X13-0064) and all participating hospitals. Trial Registration: Australia and New Zealand Clinical Trials Registry ACTRN1261300128871.
: The authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. B.E.K. reported receiving personal fees from Roche and Novartis for lectures and advisory board membership, as well as non-financial support from Amgen, for work outside of the submitted work.
: This study was funded by The National Health and Medical Research Council (grant number APP 1050596) and is administered through the University of Sydney.
: This work is published under the standard license to publish agreement. After 12 months the work will become freely available and the license terms will switch to a Creative Commons Attribution 4.0 International (CC BY 4.0)